Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average - Here's Why

Shares of Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.72 and traded as low as $0.51. Vaxart shares last traded at $0.52, with a volume of 1,118,684 shares traded.

Vaxart Stock Up 6.7 %

The firm has a 50 day moving average of $0.67 and a two-hundred day moving average of $0.72. The firm has a market capitalization of $130.89 million, a price-to-earnings ratio of -1.40 and a beta of 1.69.

Institutional Investors Weigh In On Vaxart

Hedge funds have recently made changes to their positions in the stock. Graham Capital Management L.P. increased its position in Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 32,482 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after buying an additional 35,213 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Vaxart by 48.6% during the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after buying an additional 24,803 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after acquiring an additional 122,387 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after acquiring an additional 17,942 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.